Are you Dr. Chopra?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9400 Brighton Way
Suite # 410
Beverly Hills, CA 90210Phone+1 310-858-1787Fax+1 310-858-3787
Summary
- Dr. Rajesh Chopra, MD is an otolaryngologist in Beverly Hills, California. He is currently licensed to practice medicine in California, Texas, and Massachusetts. He is affiliated with Greater Los Angeles HCS.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Otolaryngology - Head and Neck Surgery, 1997 - 2003
University of California, Irvine, School of MedicineClass of 1997
Certifications & Licensure
TX State Medical License 2015 - 2026
CA State Medical License 1999 - 2025
MA State Medical License 2003 - 2006- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
Publications & Presentations
PubMed
- 49 citationsCereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupu...Peter H. Schafer, Ying Ye, Lei Wu, Jolanta Kosek, Garth E. Ringheim
Annals of the Rheumatic Diseases. 2018-10-01 - 40 citationsPomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myelomaEmily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten
British Journal of Haematology. 2016-03-01 - 43 citationsAbsence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.Anjan Thakurta, Anita Gandhi, Michelle Waldman, Chad C. Bjorklund, Yuhong Ning
Leukemia. 2014-05-01
Press Mentions
Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-Based Protein Degradation PlatformSeptember 24th, 2020- Monte Rosa Therapeutics Discloses $32.5 Million FinancingMay 26th, 2020
Versant Ventures Strengthens Global Team and Discovery Engine InfrastructureMarch 10th, 2020- Join now to see all
Professional Memberships
- Member
